Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2018

30.08.2016 | comment – reprint

Developments in neuro-oncology

verfasst von: MD Silvia Hofer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

A short statement on the most recent developments in the neuro-oncology field, including the new WHO Classification of Tumors of the Central Nervous System (2016) and current treatment strategies.
Literatur
2.
Zurück zum Zitat Seystahl K, Gramatzki D, Roth P, Weller M. Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. Expert Opin Pharmacother. 2016;17(9):1259–70. CrossRefPubMed Seystahl K, Gramatzki D, Roth P, Weller M. Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. Expert Opin Pharmacother. 2016;17(9):1259–70. CrossRefPubMed
5.
Zurück zum Zitat Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 CrossRefPubMedPubMedCentral Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50. CrossRefPubMed van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50. CrossRefPubMed
7.
Zurück zum Zitat Faulkner C, Ellis HP, Shaw A, et al. BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15-9 fusions are more frequent in the midline than within the cerebellum. J Neuropathol Exp Neurol. 2015;74(9):867–72. CrossRefPubMedPubMedCentral Faulkner C, Ellis HP, Shaw A, et al. BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15-9 fusions are more frequent in the midline than within the cerebellum. J Neuropathol Exp Neurol. 2015;74(9):867–72. CrossRefPubMedPubMedCentral
Metadaten
Titel
Developments in neuro-oncology
verfasst von
MD Silvia Hofer
Publikationsdatum
30.08.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0278-0

Weitere Artikel der Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018 Zur Ausgabe